Allogeneic stem cell therapy allows "off the shelf" cells to be used in therapy, rather than having to take cells from each individual patient, allowing a relatively fast and inexpensive therapy.

Recently, the area of inflammation and immunology has sparked significant interest due to remarkable clinical efficacy demonstrated by autologous cell therapy ... for off-the-shelf cell therapies.

Taysha Gene Therapies (NASDAQ:TSHA) filed a prospectus for a mixed shelf offering of up to $300 million. The preliminary ...

or 'off-the-shelf,' CAR T-cell therapies. Unlike the traditional approach that requires extracting and modifying a patient's own cells (autologous therapy), allogeneic CAR T-cell therapy uses T ...

Dr. Reisner is chair of the scientific advisory board for Cell Source and has equity in the company. These financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee ...

Bria-OTS+™ is an Off-The-Shelf (i.e. pre-manufactured and ready ... This innovative approach is set to address major challenges in cancer therapy, including effective antigen selection, T ...

This innovation brings the field closer to realizing off-the-shelf CAR-T therapies ... donor-derived CAR-T therapy and improve the accessibility of stem cell transplants and organ transplants.